These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17960386)

  • 21. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.
    Sweeney CJ; Roth BJ; Kabbinavar FF; Vaughn DJ; Arning M; Curiel RE; Obasaju CK; Wang Y; Nicol SJ; Kaufman DS
    J Clin Oncol; 2006 Jul; 24(21):3451-7. PubMed ID: 16849761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weekly infusional high-dose 5-fluorouracil and leucovorin and biweekly cisplatin: a convenient treatment option in advanced gastric cancer.
    Kundel Y; Purim O; Figer A; Stemmer SM; Tichler T; Sulkes J; Sulkes A; Brenner B
    Med Sci Monit; 2008 Apr; 14(4):CR190-5. PubMed ID: 18376346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study.
    John W; Picus J; Blanke CD; Clark JW; Schulman LN; Rowinsky EK; Thornton DE; Loehrer PJ
    Cancer; 2000 Apr; 88(8):1807-13. PubMed ID: 10760756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
    Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
    Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer.
    Llombart-Cussac A; Martin M; Harbeck N; Anghel RM; Eniu AE; Verrill MW; Neven P; De Grève J; Melemed AS; Clark R; Simms L; Kaiser CJ; Ma D
    Clin Cancer Res; 2007 Jun; 13(12):3652-9. PubMed ID: 17575230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
    J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer.
    Martin M; Blasinska-Morawiec M; Salas JF; Falcon S; Rolski J; Ferrari BL; Gulyas S; Liu Y; Benhadji KA
    Clin Breast Cancer; 2009 Aug; 9(3):155-60. PubMed ID: 19661038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer.
    Chen JS; Rau KM; Chen YY; Huang JS; Yang TS; Lin YC; Liau CT; Lee KD; Su YC; Kao RH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):819-25. PubMed ID: 18663448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
    Nakajo A; Hokita S; Ishigami S; Miyazono F; Etoh T; Hamanoue M; Maenohara S; Iwashita T; Komatsu H; Satoh K; Aridome K; Morita S; Natsugoe S; Takiuchi H; Nakano S; Maehara Y; Sakamoto J; Aikou T;
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1103-9. PubMed ID: 18317763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
    Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA drug approval summaries: pemetrexed (Alimta).
    Hazarika M; White RM; Johnson JR; Pazdur R
    Oncologist; 2004; 9(5):482-8. PubMed ID: 15477632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.
    Vergote I; Calvert H; Kania M; Kaiser C; Zimmermann AH; Sehouli J
    Eur J Cancer; 2009 May; 45(8):1415-23. PubMed ID: 19168349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.
    O'Shaughnessy JA; Clark RS; Blum JL; Mennel RG; Snyder D; Ye Z; Liepa AM; Melemed AS; Yardley DA
    Clin Breast Cancer; 2005 Jun; 6(2):143-9. PubMed ID: 16001992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
    Pivot X; Raymond E; Laguerre B; Degardin M; Cals L; Armand JP; Lefebvre JL; Gedouin D; Ripoche V; Kayitalire L; Niyikiza C; Johnson R; Latz J; Schneider M
    Br J Cancer; 2001 Sep; 85(5):649-55. PubMed ID: 11531245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site.
    Park YH; Ryoo BY; Choi SJ; Yang SH; Kim HT
    Jpn J Clin Oncol; 2004 Nov; 34(11):681-5. PubMed ID: 15613558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
    Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
    Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-center phase II trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer.
    Sun Q; Liu C; Zhong H; Zhong B; Xu H; Shen W; Wang D
    Jpn J Clin Oncol; 2009 Apr; 39(4):237-43. PubMed ID: 19264768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.